Mirtazapine is a tetracyclic antidepressant commonly prescribed for depression, and off label for insomnia and appetite loss, often because it tends to be sedating at lower doses. Employees and applicants who take it sometimes ask whether it can trigger an unexpected positive result on a workplace urine drug screen, particularly on the amphetamine panel or, less commonly, on an LSD test. This post explains what immunoassay screening actually measures, what is known and not known about mirtazapine and cross reactivity, and what the confirmation and medical review officer process is designed to catch before any result becomes a problem for the employee or the employer.
How a standard urine drug screen actually works
Most workplace and clinical urine panels start with an immunoassay. That method uses antibodies designed to bind to a target drug or drug class. It is fast and inexpensive, which is why it is used for initial screening, but antibodies are not perfectly selective. They can also bind to other molecules that happen to share part of the target drug's shape, a phenomenon toxicologists call cross reactivity. When that happens on a screen, the result is reported as presumptive positive, not confirmed positive.
Federal workplace testing programs, and most private employer programs modeled on them, never rely on a single immunoassay for an adverse decision. A presumptive positive on the initial screen is retested on the same specimen using a chromatography and mass spectrometry method, usually gas chromatography mass spectrometry (GC MS) or liquid chromatography tandem mass spectrometry (LC MS/MS). These methods identify the exact molecule present, not just a class of similarly shaped molecules, and they are far less prone to the kind of cross reactivity that produces false positives on immunoassays.
Why mirtazapine comes up in false positive questions
Mirtazapine's chemical structure is a piperazino azepine, meaning it carries a piperazine ring fused into a larger ring system. That detail matters because piperazine containing compounds are a recognized source of cross reactivity on amphetamine class immunoassays. The best documented example in the published literature is not mirtazapine but a related antidepressant, trazodone, whose metabolite meta chlorophenylpiperazine (m CPP) has been shown in controlled laboratory testing to cross react with a commercial amphetamines immunoassay, producing false positive results that did not confirm on GC MS or LC MS/MS.
Mirtazapine itself has not been the subject of the same kind of published, controlled cross reactivity study. What does exist is a smaller body of evidence: individual case reports in clinical literature and adverse event submissions to the FDA's Adverse Event Reporting System (FAERS) that list mirtazapine as the suspected medication associated with a "drug screen false positive" reaction. FAERS reports are not proof of causation on their own, since they are voluntary and unverified, but they do show that clinicians have submitted this specific association enough times for it to appear in the federal database, alongside a broader pharmacovigilance literature describing antidepressants as a class among the more common sources of false positive amphetamine screens.
LSD immunoassays add a separate wrinkle. They are used far less often than amphetamine or opiate panels, and the published toxicology literature already documents false positive LSD screens caused by a range of unrelated medications, including certain antihistamines, antiemetics, and a mucolytic agent, in patients confirmed by more specific methods to have no LSD in their urine. That pattern shows LSD immunoassays in general have a documented history of nonspecific binding. It is one more reason any single LSD screen should be treated as presumptive rather than final, regardless of what medication is suspected of causing it.
The honest summary is this: mirtazapine causing an amphetamine or LSD immunoassay false positive is plausible on structural grounds and has been reported in adverse event data, but it is not backed by the same level of published, controlled evidence as some other medications on this list. Anyone relying on this information for a specific test result should not guess. The confirmation process below exists precisely to resolve that uncertainty with a specific, verified answer.
Screening panels compared to confirmation testing
| Panel | What the initial immunoassay is designed to detect | Documented or reported nonamphetamine, nonhallucinogen interferents | How it gets resolved |
|---|---|---|---|
| Amphetamine and methamphetamine (AMP, mAMP) | Amphetamine, methamphetamine, and related compounds | Bupropion, trazodone's m CPP metabolite, methylphenidate metabolites, certain decongestants, and, per FAERS submissions, mirtazapine | GC MS or LC MS/MS confirmation identifies the exact substance present or absent |
| LSD | Lysergic acid diethylamide | Certain antihistamines, antiemetics, and a mucolytic agent documented in published case series | Confirmation by a chromatography based method; LSD panels are rarely part of standard federal panels for this reason |
What happens after a presumptive positive screen
In any regulated or well run workplace program, a presumptive positive screen never goes straight to an employer as a final result. The specimen goes to confirmation testing first. If confirmation is positive, a medical review officer (MRO), a licensed physician trained in this specific process, reviews the result. The MRO contacts the employee directly, asks about current prescriptions, and reviews documentation such as a pharmacy record or a prescription label. If a legitimate medical explanation accounts for the result, the MRO reports the test as negative to the employer. Only results the MRO cannot explain medically are reported as positive.
Employees who take mirtazapine, or any prescription medication, should keep basic proof of the prescription available, such as a pharmacy printout or the prescribing physician's contact information, and should disclose current medications to the collector or the MRO's office when asked. That documentation is what allows the MRO process to work as intended.
What this means for employers
Employers should not treat a single immunoassay result as evidence of drug use, and should never make an adverse employment decision based on a screen that has not gone through confirmation and MRO review. Federal drug testing rules, and most responsible non federal programs modeled on them, build this two step structure in specifically because immunoassay cross reactivity is a known and ongoing limitation of the technology, not a rare fluke. Building a testing program that documents medications, uses a certified laboratory, and routes every non negative screen through an MRO protects both the accuracy of the program and the rights of employees taking legitimate prescriptions.
Frequently asked questions
Can mirtazapine cause a false positive drug test for amphetamines?
It is possible. Mirtazapine's structure includes a piperazine ring, a feature linked to amphetamine immunoassay cross reactivity in a related antidepressant, and mirtazapine appears as the suspected medication in FDA adverse event reports describing a false positive drug screen. Published, controlled cross reactivity data specific to mirtazapine is limited, so any presumptive positive should go to confirmation testing rather than being treated as a definite answer either way.
Can mirtazapine cause a false positive for LSD?
LSD immunoassays have a documented history of nonspecific reactions to several unrelated medications, and mirtazapine is sometimes raised in this context, but strong published evidence specific to mirtazapine and LSD panels is limited. Because LSD screens in general are known to produce false positives, any presumptive positive result needs confirmation by a chromatography based method before it means anything.
Will a lab automatically report a positive screen to my employer?
No, not in a properly run program. A presumptive positive on the initial immunoassay is retested using a confirmation method, and a medical review officer reviews any confirmed positive before it is reported to the employer, including checking for a legitimate prescription that explains the result.
What should I do if I test positive while taking mirtazapine?
Tell the collector or the MRO's office about the prescription when asked, and have documentation such as a pharmacy record or the prescriber's contact information ready. This is not medical or legal advice, and questions about a specific result should go to the MRO handling the test.
Does confirmation testing use the same method as the initial screen?
No. The initial screen is an antibody based immunoassay. Confirmation uses gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry, methods that identify the specific molecule present rather than a class of similarly shaped molecules, which is why confirmation resolves most immunoassay cross reactivity.
Is mirtazapine itself a controlled substance that shows up on standard panels?
No. Mirtazapine is not a controlled substance and standard workplace panels are not designed to detect it directly. Any positive result associated with mirtazapine use would be a cross reactivity effect on a different panel, such as the amphetamine panel, not a direct detection of mirtazapine.
Sources
- SAMHSA, Frequently Asked Questions About Federal Workplace Drug Testing
- SAMHSA, Medical Review Officer Guidance Manual
- Electronic Code of Federal Regulations, 49 CFR Part 40 Subpart G, Medical Review Officers and the Verification Process
- National Library of Medicine, PubMed Central, Discovering Cross Reactivity in Urine Drug Screening Immunoassays Through Large Scale Analysis of Electronic Health Records
- U.S. Food and Drug Administration, FDA Adverse Event Reporting System (FAERS) Public Dashboard
Related reading
Employers building or reviewing a testing program can compare drug test cups designed for defensible, panel based screening as part of a full confirmation and MRO workflow.
This article is general information only, not medical or legal advice. Employers and employees with questions about a specific test result or testing policy should consult a medical review officer, qualified counsel, or the applicable federal or state regulatory guidance.
